The new-still premature drug, working title SCO-101, is intended to ensure that breast cancer tumor cells are no longer resistant to the drug used to treat them. This resistance occurs in a significant proportion of breast cancer patients treated with tamoxifen. This is a drug that is prescribed as a follow-up treatment to prevent any metastases from growing into new tumors.
For all currently known genes that cause the tumor cell to become resistant to tamoxifen, he will investigate whether SCO-101 is able to reverse the resistance. And if so, try to clarify through which mechanism SCO-101 accomplishes this.